Inhibrx, Inc. (INBX)

Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -15.48% and 21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

• 
  LegalZoom (LZ) Q2 Earnings and Revenues Surpass Estimates

  Zacks
• 
  Strattec Security (STRT) Q4 Earnings Miss Estimates

  Zacks

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the second quarter of 2022 and provided an update on recent corporate highlights.

• 
  Zealand Pharma Announces Financial Results for the First Half of 2022

  GlobeNewswire
• 
  Good Times Restaurants Reports Results for the Fiscal Third Quarter Ended June 28, 2022

  Business Wire

Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance

Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a robust preclinical pipeline, today announced the completion of Phase 1 dose escalation of INBRX-105, a novel targeted 4-1BB agonist, in combination with Keytruda®. It also reported the funding of an additional $60 million from its Loan and Security Agreement, as amended (the "Loan Agreement"), with Oxford Finance, LLC ("Oxford"), to bring its cash balance to approximately $176 million as of Jun